证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023003 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | □现场参观 □其他 东北证券 方心宇；国泰基金 姜英；源峰基金 耿华；新华基金 赵 参与单位名 称及人员 姓名 东宇；工银瑞信 丁洋；民生加银 郝梦娇；星石投资 朱宇希；东吴 基金 吴佳歆；长江养老 叶小桃；淳厚基金 严定安；九泰基金 王 宇鸿；太平基金 赵超；嘉实基金 程佳 时 间 2023 年 5 月 26 日 地 点 公司会议室+腾讯会议 上市公司接 待人员姓名 董事长、总经理宋侃先生，副总经理张东刚先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司活性生物骨产品的进展情况如何？ 答：公司的活性生物骨产品正在做相关的转产验证工作 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023002 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | √现场参观 □其他 深圳市徐星私募 张东伟；杭州哲云私募 丁谢峰；个人投资者 徐方 参与单位名 称及人员 姓名 云、赵连平、姜荣光、刘凡、王居福、邹萍萍、陈建花、胡荣雁； 证券日报 彭春来、赵宁、赵彬彬、王僖等人 时 间 2023 年 5 月 10 日、2023 年 5 月 11 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司的业绩及分红情况如何？ 答：回顾过去几年公司业绩保持稳定增长。2017 年至 2022 年，营业收入由 1.83 亿元增长至 4.33 亿元， ...

Financial Performance - The company's revenue for Q1 2023 was ¥109,080,515.27, representing a decrease of 7.35% compared to ¥117,732,128.60 in the same period last year[5] - Net profit attributable to shareholders was ¥53,398,823.33, down 2.95% from ¥55,019,970.53 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 109,080,515.27, a decrease from CNY 117,732,128.60 in the previous period[19] - Net profit for Q1 2023 was CNY 53,398,823.33, compared to CNY 55,019,970.53 in the same period last year, reflecting a decline of approximately 2.9%[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.30, slightly lower than CNY 0.31 in the previous year[20] Cash Flow and Liquidity - Operating cash flow net amount decreased by 20.45% to ¥51,412,656.21 from ¥64,628,035.53 in the previous year[5] - The net cash flow from operating activities was ¥51,412,656.21, a decrease of 20.4% compared to ¥64,628,035.53 in the previous period[22] - Cash inflow from operating activities totaled ¥115,002,511.65, down from ¥123,118,084.20, reflecting a decline of 6.4%[22] - Cash outflow from operating activities increased to ¥63,589,855.44 from ¥58,490,048.67, representing an increase of 8.5%[22] - The net cash flow from investment activities was ¥83,072,126.87, a significant improvement from -¥16,860,975.69 in the previous period[22] - The net increase in cash and cash equivalents was ¥134,484,783.08, compared to ¥47,767,059.84 in the previous period, indicating a substantial increase[23] - The ending balance of cash and cash equivalents was ¥191,530,405.87, up from ¥160,415,416.11, reflecting a growth of 19.4%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,019,909,889.77, reflecting a 3.34% increase from ¥986,904,775.50 at the end of the previous year[5] - Total liabilities decreased to CNY 101,403,274.79 from CNY 121,796,983.85, indicating a reduction of about 16.8%[18] - The total equity attributable to shareholders increased to CNY 918,506,614.98 from CNY 865,107,791.65, marking an increase of approximately 6.2%[18] - The total current assets amount to ¥747,503,222.35, up from ¥710,006,315.27, indicating an increase of 5.2%[16] - The total fixed assets increased to ¥223,077,762.64 from ¥213,402,856.90, reflecting a growth of 4.0%[16] Research and Development - Research and development expenses increased by 56.26% to ¥11,822,835.70, driven by more clinical stage projects[8] - Research and development expenses rose significantly to CNY 11,822,835.70 from CNY 7,565,929.03, reflecting an increase of about 56.5%[19] - The company has entered clinical trials for its product, the intrauterine repair membrane, as of February 21, 2023[13] - The company received acceptance for its medical device registration application for phosphoric acid etching agent on March 21, 2023[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13.615 million[11] - The largest shareholder, Mipo Hai, holds 33.87% of shares, totaling 60,961,500 shares, with 16 million shares pledged[11] - The company has a total of 10 major shareholders with varying ownership percentages, the largest being 33.87%[11] Other Financial Metrics - The weighted average return on equity decreased to 5.99% from 6.77% in the previous year[5] - The company reported a significant decrease of 88.52% in other operating income, amounting to ¥1,540.02 compared to ¥13,412.00 in the previous year[9] - Investment income for the period was ¥6,914,978.50, a notable increase from zero in the same period last year[8] - The company experienced a 162.11% increase in credit impairment losses, totaling -¥79,228.07, due to higher bad debt provisions[8] - The company reported a financial income of CNY 337,646.29, up from CNY 239,121.92 in the previous period[19] - The deferred income tax assets decreased slightly to CNY 2,646,980.29 from CNY 2,668,398.16[17] - The company reported a cash outflow of ¥3,441,000.76 for purchasing goods and services, down from ¥8,199,637.22, a decrease of 58.1%[22] - The company paid ¥23,647,235.15 in employee compensation, a decrease from ¥25,934,195.12, indicating a reduction of 8.8%[22] - The company did not report any cash inflow from financing activities during the period[22]

Revenue and Financial Performance - The company's operating revenue for 2022 was ¥433,224,730.58, an increase of 8.26% compared to ¥400,175,251.94 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥185,436,805.06, reflecting a growth of 10.02% from ¥168,552,584.39 in 2021[28]. - The net profit after deducting non-recurring gains and losses was ¥172,608,159.41, up 7.29% from ¥160,878,004.21 in 2021[28]. - The net cash flow from operating activities increased by 13.06% to ¥187,838,040.27 in 2022 from ¥166,134,014.20 in 2021[28]. - Basic earnings per share rose by 36.17% to ¥1.28 in 2022, compared to ¥0.94 in 2021[28]. - Total assets at the end of 2022 reached ¥986,904,775.50, a 6.24% increase from ¥928,920,991.12 at the end of 2021[28]. - The net assets attributable to shareholders increased by 10.17% to ¥865,107,791.65 at the end of 2022 from ¥785,270,986.59 at the end of 2021[28]. - The company achieved a net profit of 185.44 million yuan in 2022, representing a year-on-year growth of 10.02%[49]. - Total revenue for 2022 reached 433.22 million yuan, an increase of 8.26% compared to the previous year[50]. Product Development and Market Position - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which have experienced rapid growth in recent years[5]. - The company is focused on regenerative medicine, aiming to develop innovative products to meet clinical needs[36]. - The company’s R&D efforts are aimed at developing new products, although the process is lengthy and involves significant investment[7]. - The company has successfully registered new products including "self-etching adhesive" and "active biological bone," expanding its product offerings[45]. - The company is currently conducting clinical trials for several key projects, including light-cured composite resin and calcium silicate bioceramic bone repair materials[79]. - The company is in the process of launching new products, including a breast patch for reconstruction and a uterine cavity repair membrane[79]. - The company is actively developing new products and technologies, with a focus on enhancing the efficacy of its active biological bone and skin repair membrane[110]. Risk Management and Challenges - The company emphasizes the importance of enhancing management capabilities and market expansion to mitigate potential risks from external changes[5]. - The company is focused on addressing risks related to product concentration and external environmental changes, which could affect future growth[5]. - Regulatory changes and external environment shifts, including centralized procurement policies, present ongoing challenges for maintaining market competitiveness[105]. - The company faces risks due to a concentrated product portfolio, with a focus on regenerative medicine and ongoing development of new products like active biological bone and second-generation dura membranes[104]. - Product quality is critical, as any issues could adversely affect both health outcomes and the company's operations[106]. Governance and Management - The company has established a governance structure that ensures compliance with relevant laws and regulations, enhancing operational transparency and risk management[113]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, achieving a "five independence" standard[117]. - The company has a strong management team with members holding advanced degrees and extensive experience in the biotechnology and pharmaceutical sectors[126]. - The company has appointed several independent directors with significant experience in finance and management to strengthen its governance[124]. Shareholder Engagement and Profit Distribution - The profit distribution plan approved by the board is a cash dividend of 6.00 RMB per 10 shares (including tax), with no bonus shares issued[7]. - The company aims to distribute at least 20% of the annual distributable profit as cash dividends, increasing to 10% if there are significant investment plans or cash expenditures[145]. - The company has maintained a stable profit distribution policy, with adjustments requiring thorough research and approval from the board and shareholders[150]. - The board of directors will consider shareholder feedback, especially from minority shareholders, when proposing cash dividend plans[148]. - The company distributed a cash dividend of RMB 105.6 million to shareholders, with a distribution of RMB 8.80 per 10 shares[166]. Market Expansion and Sales Strategy - The company has successfully participated in volume-based procurement in six provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[5]. - The company is focusing on expanding its market presence and product applications, particularly in the fields of oral repair and neurosurgery[110]. - The company actively participated in around 750 academic activities to enhance market presence and brand recognition[52]. - The company has over 1,100 distributors nationwide, ensuring a broad marketing network and strong brand recognition in the market[62]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[110]. Quality Management and Compliance - The company has established a comprehensive quality management system, achieving ISO 13485 and ISO 9001 certifications[64]. - The quality management system maintained a 100% pass rate for product inspections, ensuring stable and effective quality management throughout the reporting period[57]. - The company has implemented a supplier evaluation management system, conducting annual assessments to control product quality from the source[171]. - The company has established a monitoring group for adverse events related to product quality, ensuring rapid response and consumer protection[170]. - The internal control system has been strengthened to ensure compliance with laws and regulations, enhancing risk management and operational efficiency[155]. Employee Development and Welfare - The total number of employees at the end of the reporting period is 376, with 163 in production, 105 in sales, 61 in technical roles, 7 in finance, and 40 in administration[140]. - The company has established a comprehensive employee welfare system, providing nearly 20 types of benefits[168]. - The company has conducted training programs to enhance employee skills and support business innovation[168]. - The company emphasizes continuous and stable profit distribution policies, prioritizing cash dividends over stock dividends[144]. Environmental Responsibility - The company has implemented various environmental protection measures, including the installation of pollution control equipment and the use of natural gas boilers[162]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[163]. - Environmental protection measures include the installation of various eco-friendly equipment, ensuring compliance with local environmental regulations[171].

2022 年度网上业绩说明会 证券代码：300653 证券简称：正海生物 公告编号：2023-024 欢迎广大投资者积极参与！ 特此公告。 烟台正海生物科技股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）2022 年年度报告全文 及摘要已于 2023 年 4 月 11 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。为便于投资者能够进一步了解公司的生产经营情况， 公司将于 2023 年 4 月 12 日（周三）15:00-17:00 在机会宝和中国证券报·中证 网举办 2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式 举行，投资者可登录机会宝（https://n.jhbshow.com/live-text/2124749310 或扫描下 方二维码）和中证路演中心（https://www.cs.com.cn/roadshow/yjsmh/300653_2022/） 参与本年度业绩说明会 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------|---------| | 投资者关系 活动类别 | þ \n□ | 特定对象调研 □媒体采访 □分析师会议 \n新闻发布会 □业绩说明会 □路演活动 | 编号： | 2017001 | | | □ 现场参观 □其他： | | 海通证券贺文斌，德传医疗姜广策，兴业证券张佳博，东吴证券许汪洋，华创 | | | 参与单位名称 及人员姓名 | | | 证券宋凯，雷钧资产李武跃，硕估投资苏志敏，首善财富徐迅捷 | ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020002 | --- | --- | --- | --- | |-----------------|----------------------------------------------------------|------------------------------------|-------| | | | | | | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | | □新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | 上海中润投资 唐煜 | | | | 名称及人员 姓名 | 中信证券 陈旺 | | | | 时 间 | 2020 年 5 月 21 | 日 下午 2:30-3:30 | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | 上市公司 | | | | | 接待人员 | | 副总经理、董事会秘书：陆美娇女士 | | | 姓名 | | | | | | | 投资者关系 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020001 | --- | --- | --- | --- | |-----------------|--------------------------|----------------------------------------|------------------------------------------------------| | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | | □新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | | 上海恒复投资—周小钢，长城证券—穆云吉， | | | 名称及人员 姓名 | | | 个人投资者夏菊、姜荣光、赵连平、李君兰、李发亮、周洁 | | 时 间 | 2020 年 5 月 20 | 日 下午 3:00—4:00 | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | | 董事长：王涛先生 | | | | 上市公司 | 董事、总 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020004 | --- | --- | --- | --- | |-----------------|-------------------------|----------------------------------------------------------|-------| | | | | | | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | □ | 新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | | 平安证券 叶寅、民生证券 盛丽华、大成基金 李林益 | | | 名称及人员 姓名 | | 建信基金 王丽媛、前海开源基金 詹世乾 | | | 时 间 | 2020 年 6 月 10 | 日 下午 3:00-4:30 | | | | | | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | 上市公司 | 董事长：王涛先生 | | | | 接待人员 姓名 | | 副总经理、 ...